Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Cash flows from operating activities:
Net loss			$ (10,143,939)	$ (10,063,912)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			16,286	16,890
Stockbased compensation			369,117	363,408
Foreign currency loss (gain)	$ 5,691	$ 35,494	86,618	(15,180)
Changes in operating assets and liabilities:
Prepaid expenses and other current and noncurrent assets			517,745	398,531
Accounts payable			(715,625)	(515,964)
Accrued expenses			(63,349)	299,387
Deferred grant revenue				(528,974)
Net cash used in operating activities			(9,933,147)	(10,045,814)
Cash flows from investing activities:
Purchases of property and equipment				(15,478)
Net cash used in investing activities				(15,478)
Cash flows from financing activities:
Proceeds from issuance of common stock			834,397	15,999,598
Common stock issuance costs			(35,729)	(1,312,108)
Net cash provided by financing activities			798,668	14,687,490
Change in cash, cash equivalents and restricted cash			(9,134,479)	4,626,198
Effect of exchange rate changes on cash, cash equivalents and restricted cash			3,406	17,427
Cash, cash equivalents and restricted cash-beginning of year			22,890,055	21,647,537	$ 21,647,537
Cash, cash equivalents and restricted cash-end of period	13,758,982	26,291,162	13,758,982	26,291,162	22,890,055
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	13,718,052	26,249,625	13,718,052	26,249,625	22,849,885
Restricted cash	40,930	41,537	40,930	41,537	40,170
Total cash, cash equivalents and restricted cash	$ 13,758,982	$ 26,291,162	13,758,982	$ 26,291,162	$ 22,890,055
Non-cash investing and financing activities:
Conversion of Series A convertible preferred stock to common stock			$ 583,702